Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrati
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NEUROCRINE BIOSCIENCES, INC.

(NBIX)
  Rapporto
Tempo reale stimato Cboe BZX  -  19:18:22 29/03/2023
97.17 USD   +0.78%
28/03Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2023 Virtual CNS Days, Mar-28-2023 12:30 PM
CI
15/03Transcript : Neurocrine Biosciences, Inc. Presents at Barclays Global Healthcare Conference, Mar-15-2023 10:45 AM
CI
09/03Neurocrine Biosciences, Inc. annuncia i nuovi dati dello studio RE-KINECT pubblicati nel Journal of Patient-Reported Outcomes
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietÓFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su NEUROCRINE BIOSCIENCES, INC.
13:55Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer's ..
12:09Neurocrine Biosciences Inc: Other Events (form 8-K)
21/03Neurocrine Biosciences to Present at the Stifel 2023 CNS Days
10/03Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA Ca..
09/03Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Pub..
09/03Neurocrine Biosciences, Inc. Announces New Data from RE-KINECT Study Published in the J..
09/03Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA« (..
09/03Neurocrine Biosciences, Inc. Presents Data from Three in Vitro Dissolution Studies Expl..
08/03Neurocrine Biosciences to Participate at Investor Conferences in March
06/03Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of IN..
03/03Neurocrine Biosciences, Inc. Presents Data Analyzing the Long-Term Outcomes of Treating..
24/02Neurocrine Biosciences: Purchase Agreement - Form 8-K
24/02Neurocrine Biosciences Inc: Other Events (form 8-K)
14/02Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Dis..
14/02Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collabora..
10/02Neurocrine Biosciences Inc: Amendments to Articles of Inc. or Bylaws; Change in Fiscal Ye..
09/02NEUROCRINE BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition..
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
09/02Insider Sell: Neurocrine Biosciences
07/02Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference
07/02Jerome returns in the second week
06/02Neurocrine Biosciences Q4 Non-GAAP Earnings, Revenue Rise
06/02Neurocrine Biosciences, Inc. Provides Revenue Guidance for the Year 2023
06/02Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Reports Q4 Revenue $412M, vs. Street Est o..
06/02Neurocrine: Q4 Earnings Snapshot
06/02Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Y..
06/02Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q4 EPS $1.24, vs. Street Est of $1.4..
06/02Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Pro..
06/02North American Morning Briefing: Payrolls -3-
02/02Insider Sell: Neurocrine Biosciences
02/02Insider Sell: Neurocrine Biosciences
02/02Insider Sell: Neurocrine Biosciences
17/01Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year..
09/01Neurocrine Biosciences, Voyager Therapeutics to Develop, Commercialize Gene Therapies f..
09/01Neurocrine Biosciences Inc: Entry into a Material Definitive Agreement, Financial Stateme..
09/01Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Devel..
09/01Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Devel..
06/01Insider Sell: Neurocrine Biosciences
06/01Insider Sell: Neurocrine Biosciences
03/01Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022Neurocrine Biosciences Says US FDA Accepts Supplemental NDA for Valbenazine for Chorea ..
2022Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for..
2022Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Applicati..
2022Neurocrine Biosciences Says Prospective Epilepsy Drug Did Not Meet Endpoint in Mid-Stag..
2022Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Pati..
2022Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Pati..
2022Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediat..
2022Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediat..
2022Insider Sell: Neurocrine Biosciences
2022Insider Sell: Neurocrine Biosciences
2022Insider Sell: Neurocrine Biosciences
2022Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
2022Insider Sell: Neurocrine Biosciences
2022Insider Sell: Neurocrine Biosciences
2022Insider Sell: Neurocrine Biosciences
2022Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating ..
2022Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating ..
2022Insider Sell: Neurocrine Biosciences
2022Insider Sell: Neurocrine Biosciences
2022Diurnal Shares Delisted After Neurocrine Biosciences Takeover
2022NEUROCRINE BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition..
2022Top Midday Gainers
2022Neurocrine Biosciences Q3 Non-GAAP Earnings, Revenue Rise
2022Diurnal's Takeover Scheme By US-based Neurocrine Biosciences Becomes Effective
2022Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 EPS $1.08, vs. Street Est of $1.1..
2022Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 Revenue $387.9M, vs. Street Est o..
2022Earnings Flash (NBIX) NEUROCRINE BIOSCIENCES Posts Q3 EPS $1.08, vs. Street Est of $1.1..
2022Neurocrine: Q3 Earnings Snapshot
2022Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 ING..
2022Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
2022Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022
2022Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) comple..
2022Insider Sell: Neurocrine Biosciences
2022TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility
2022Neurocrine Biosciences Starts Phase 2 Trial of NBI-1117568 to Treat Schizophrenia
2022Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adult..
2022Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adult..
2022Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics ..
2022Neurocrine Biosciences, Inc. Presents Real-World Parkinson's Disease Patient Characteri..
2022Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antip..
2022Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Fina..
2022Insider Sell: Neurocrine Biosciences
2022Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer
2022Neurocrine Biosciences, Inc. Announces That Dr. Ingrid Delaet Will Join the Company's E..
2022Capitulation ahead?
2022Analyst recommendations: Anglo American, Aveva, BP pc, Costco, F..
2022Neurocrine Biosciences Presents INGREZZA Data on Sustained Treatment Response at Psych ..
2022Neurocrine Biosciences Says Study Showed 'Sustained' Improvement With Valbenazine in Ad..
2022Neurocrine Biosciences Presents INGREZZA« (valbenazine) Data on Sustained Treatment Res..
2022Neurocrine Biosciences Presents INGREZZA(R) (valbenazine) Data on Sustained Treatment R..
2022Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS Capsules Effect on CO..
2022Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Educati..
2022Neurocrine Biosciences, Inc. Announces to Present Study Findings on Evolving Tardive Dy..
2022Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS« (opicapone) Capsules..
Prossimo evento su NEUROCRINE BIOSCIENCES, INC.
28/03/23Stifel CNS Day
1 MarketScreener vale pi¨ di 1000 Influencer!
Registrazione 100% gratuita
fermer